基于前列腺特异性抗原的前列腺癌筛查:美国预防服务工作组证据报告与系统综述
欧洲试验显示筛查可降低前列腺癌死亡率(RR 0.79),但假阳性率17.8%、过度诊断率20.7%-50.4%,积极治疗对长期生存影响不明确且增加尿失禁和勃起功能障碍风险。
要点
- PSA筛查降低前列腺癌死亡率证据不一致,欧洲试验显示RR 0.79,美国试验无显著获益。
- 筛查伴随假阳性(17.8%)、活检并发症(0.5%-1.6%)和过度诊断(20.7%-50.4%)。
- 积极治疗(手术/放疗)对筛查检出前列腺癌的长期生存影响不明确,但增加尿失禁和勃起功能障碍。
核心结论
- PSA筛查可能降低前列腺癌死亡风险,但与假阳性结果、活检并发症和过度诊断相关。
- 与保守管理相比,对筛查检出的前列腺癌进行积极治疗对长期生存影响不明确,但与性功能和排尿困难相关。
研究设计与样本
- 检索PubMed、EMBASE、Web of Science和Cochrane注册库及数据库,时间从2011年7月1日至2017年7月15日,并于2018年2月1日进行监测检索。
- 纳入随机临床试验(RCT)评估筛查、队列研究报告危害、RCT和队列研究比较积极治疗与保守管理、以及活检前风险计算器的外部验证。
主要发现
- 过度诊断估计占筛查检出癌症的20.7%至50.4%。
- 在筛查检出前列腺癌男性的RCT(n=1,643)中,与主动监测相比,根治性前列腺切除术(HR 0.63,95%CI 0.21-1.93)和放疗(HR 0.51,95%CI 0.15-1.69)均与前列腺癌死亡率显著降低无关,但均与转移性疾病风险显著降低相关。
关键数值与推荐
- 过度诊断率为20.7%至50.4%(筛查检出的癌症)。
- 根治性前列腺切除术与尿失禁的合并RR为2.27(95%CI 1.82-2.84),与勃起功能障碍的合并RR为1.82(95%CI 1.62-2.04);放疗与勃起功能障碍的合并RR为1.31(95%CI 1.20-1.42)。
临床怎么用
- 临床医生应与患者讨论PSA筛查的潜在获益(可能降低前列腺癌死亡率)与危害(假阳性、活检并发症、过度诊断)。
- 对于筛查检出的前列腺癌,应告知患者积极治疗对长期生存影响不明确,但可能增加尿失禁和勃起功能障碍风险。
- 决策应结合患者价值观和偏好,考虑主动监测作为保守管理选项。
局限性
- 美国试验存在对照组污染,英国试验对单次PSA筛查依从性低,可能影响结果解释。
- 过度诊断估计范围较宽(20.7%-50.4%),存在不确定性。
- 积极治疗与保守管理比较的长期生存数据不明确,部分分析基于有限试验和队列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prostate cancer is the second leading cause of cancer death among US men. OBJECTIVE: To systematically review evidence on prostate-specific antigen (PSA)-based prostate cancer screening, treatments for localized prostate cancer, and prebiopsy risk calculators to inform the US Preventive Services Task Force. DATA SOURCES: Searches of PubMed, EMBASE, Web of Science, and Cochrane Registries and Databases from July 1, 2011, through July 15, 2017, with a surveillance search on February 1, 2018. STUDY SELECTION: English-language reports of randomized clinical trials (RCTs) of screening; cohort studies reporting harms; RCTs and cohort studies of active localized cancer treatments vs conservative approaches (eg, active surveillance, watchful waiting); external validations of prebiopsy risk calculators to identify aggressive cancers. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. MAIN OUTCOMES AND MEASURES: Prostate cancer and all-cause mortality; false-positive screening results, biopsy complications, overdiagnosis; adverse effects of active treatments. Random-effects meta-analyses were conducted for treatment harms. RESULTS: Sixty-three studies in 104 publications were included (N = 1 904 950). Randomization to PSA screening was not associated with reduced risk of prostate cancer mortality in either a US trial with substantial control group contamination (n = 76 683) or a UK trial with low adherence to a single PSA screen (n = 408 825) but was associated with significantly reduced prostate cancer mortality in a European trial (n = 162 243; relative risk [RR], 0.79 [95% CI, 0.69-0.91]; absolute risk reduction, 1.1 deaths per 10 000 person-years [95% CI, 0.5-1.8]). Of 61 604 men screened in the European trial, 17.8% received false-positive results. In 3 cohorts (n = 15 136), complications requiring hospitalization occurred in 0.5% to 1.6% of men undergoing biopsy after abnormal screening findings. Overdiagnosis was estimated to occur in 20.7% to 50.4% of screen-detected cancers. In an RCT of men with screen-detected prostate cancer (n = 1643), neither radical prostatectomy (hazard ratio [HR], 0.63 [95% CI, 0.21-1.93]) nor radiation therapy (HR, 0.51 [95% CI, 0.15-1.69]) were associated with significantly reduced prostate cancer mortality vs active monitoring, although each was associated with significantly lower risk of metastatic disease. Relative to conservative management, radical prostatectomy was associated with increased risk of urinary incontinence (pooled RR, 2.27 [95% CI, 1.82-2.84]; 3 trials; n = 1796) and erectile dysfunction (pooled RR, 1.82 [95% CI, 1.62-2.04]; 2 trials; n = 883). Relative to conservative management (8 cohort studies; n = 3066), radiation therapy was associated with increased risk of erectile dysfunction (pooled RR, 1.31 [95% CI, 1.20-1.42]). CONCLUSIONS AND RELEVANCE: PSA screening may reduce prostate cancer mortality risk but is associated with false-positive results, biopsy complications, and overdiagnosis. Compared with conservative approaches, active treatments for screen-detected prostate cancer have unclear effects on long-term survival but are associated with sexual and urinary difficulties.
引用
- Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 29801018. doi:10.1001/jama.2018.3712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。